Efficacy and safety of safinamide in Parkinson’s disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study
Journal of Neural Transmission · 2025
DOI: 10.1007/s00702-024-02851-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neural Transmission, 2025. Verfasst von Eungseok Oh und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Chungnam National University College of Medicine and Hospital, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Antiparkinson Agents, Alanine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eisai Korea.
Abstract (Originalsprache)
This multicentre, prospective, single-arm study evaluated safinamide as add-on therapy to levodopa in Korean patients with Parkinson’s disease (PD) with motor fluctuations with ≥ 1.5 h of “off” time daily, who took levodopa ≥ 3 times/day ( n = 199). Baseline levodopa and dopamine agonist doses were maintained without escalation during the 18-week treatment period. Participants received safinamide 50 mg/day for 2 weeks and 100 mg/day thereafter. PD diaries and questionnaires (Parkinson’s Disease Questionnaire, PDQ-39; Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale, MDS–UPDRS part 3 and part 4; King’s Parkinson’s Disease Pain Scale, KPPS; Mini-Mental State Examination, MMSE) were assessed at baseline and at week 18. Treatment-emergent adverse events (TEAEs) were recorded. Mean disease duration was 6.6 years, and mean levodopa equivalent daily dose was 721.1 mg/day. At week 18, significant improvements from baseline were seen for the co-primary endpoints, mean daily “off” time (− 1.3 ± 2.4 h, p < 0.001) and quality of life (QoL) based on PDQ-39 summary index (− 2.7 ± 10.3, p < 0.001), Moreover, significant improvements were seen in motor symptoms and motor complications (MDS-UPDRS part 3 and 4), daily “on” time without dyskinesia (all p < 0.001) and pain (KPPS; p = 0.013). TEAEs occurred in 40.2% of patients, with most being mild in severity. In conclusion, safinamide at a dosage of 100 mg/day significantly improved motor symptoms, QoL, and pain, and demonstrated a favourable safety profile without levodopa dosage escalation during the 18-week treatment period in Korean patients with PD. Trial registration number and date : NCT05312632, First Posted: April 5, 2022
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Chungnam National University College of Medicine and Hospital, Daejeon, Republic of Korea.
- Department of Neurology, School of Medicine, Dong-A University, Busan, Republic of Korea.
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
- Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Republic of Korea.
- Department of Neurology, Chung-Ang University Hospital, Seoul, Republic of Korea.
Förderung
- Eisai Korea
Zitieren
APA
Oh, E., Cheon, S. M., Cho, J. W., Sung, Y. H., Kim, J. S., Shin, H. W., Kim, J. M., Park, M. Y., Kwon, D. Y., Ma, H., Park, J. H., Koh, S. B., Choi, S. M., Park, J., Lee, P. H., Ahn, T. B., Kim, S. J., Lyoo, C. H., Lee, H. W., …, & Baik, J. S. (2025). Efficacy and safety of safinamide in Parkinson’s disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study. Journal of Neural Transmission. https://doi.org/10.1007/s00702-024-02851-6
Vancouver
Oh E, Cheon SM, Cho JW, Sung YH, Kim JS, Shin HW, et al. Efficacy and safety of safinamide in Parkinson’s disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study. Journal of Neural Transmission. 2025. doi:10.1007/s00702-024-02851-6
BibTeX
@article{Oh2025,
author = {Oh, Eungseok and Cheon, Sang-Myeong and Cho, Jin Whan and Sung, Young Hee and Kim, Joong-Seok and Shin, Hae-Won and Kim, Jong-Min and Park, Mee Young and Kwon, Do-Young and Ma, Hyeo and Park, Jeong-Ho and Koh, Seong-Beom and Choi, Seong-Min and Park, Jinse and Lee, Phil Hyu and Ahn, Tae-Beom and Kim, Sang Jin and Lyoo, Chul Hyoung and Lee, Ho-Won and Kim, Jieun and Lee, Yoona and Baik, Jong Sam},
title = {Efficacy and safety of safinamide in Parkinson’s disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study},
journal = {Journal of Neural Transmission},
year = {2025},
doi = {10.1007/s00702-024-02851-6}
}
EUVIMED